Tepotinib Hepatic Impairment Trial

Inclusion Criteria:

- Men and women (of nonchildbearing potential), with a body mass index of 18 to 36
kilograms per meter square (inclusive) and a body weight greater than or equal to 50
kilograms at screening, with the absence of acute hepatitis or Human Immunodeficiency
Virus 1 and 2, who have given informed consent and are willing and able to comply with
study procedures will be eligible for enrollment

- Participants with impaired hepatic function (Child-Pugh class A or Child-Pugh class B)
and participants with normal hepatic function will be eligible to enroll in the study

- Other protocol defined inclusion criteria could apply

Exclusion Criteria:

- Healthy participants will be excluded if they have hepatitis B or C or had a previous
infection with hepatitis C treated with Sofosbuvir or other antiviral compounds, or
any other clinically relevant disease, as considered by the Investigator

- Participants with impaired hepatic function will be excluded if they have primary
biliary liver cirrhosis, nonstabilized chronic heart failure, hepatocarcinoma, hepatic
encephalopathy (Grade III or IV), sepsis or gastrointestinal bleeding, or any other
clinically relevant disease, as considered by the Investigator

- Other protocol defined exclusion criteria could apply